Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

Christophe Massard; Heidi M. Penttinen; Egils Vjaters; Petri Bono; Vilnis Lietuvietis; Teuvo L. Tammela; Annamari Vuorela; Pirjo Nykanen; Pasi Pohjanjousi; Amir Snapir; Karim Fizazi

doi:10.1016/j.eururo.2015.09.046

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

Christophe Massard, Heidi M. Penttinen, Egils Vjaters, Petri Bono, Vilnis Lietuvietis, Teuvo L. Tammela, Annamari Vuorela, Pirjo Nykanen, Pasi Pohjanjousi, Amir Snapir, Karim Fizazi

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	European Urology
Volume	69
Issue number	5
Pages (from-to)	834-840
Number of pages	7
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2015.09.046
Publication status	Published - May 2016
MoE publication type	A1 Journal article-refereed

Fields of Science

Androgen receptor inhibitor
Castration-resistant prostate cancer
ODM-201
ENZALUTAMIDE
ANTIANDROGEN
SURVIVAL
ARN-509
3126 Surgery, anesthesiology, intensive care, radiology

Access to Document

10.1016/j.eururo.2015.09.046

Pharmacokinetics, Antitumor ActivityFinal published version, 972 KB

Cite this

Massard, C., Penttinen, H. M., Vjaters, E., Bono, P., Lietuvietis, V., Tammela, T. L., Vuorela, A., Nykanen, P., Pohjanjousi, P., Snapir, A., & Fizazi, K. (2016). Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. European Urology, 69(5), 834-840. https://doi.org/10.1016/j.eururo.2015.09.046

@article{6473020254064eff9d4d7769023ce5d7,

title = "Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study",

keywords = "Androgen receptor inhibitor, Castration-resistant prostate cancer, ODM-201, ENZALUTAMIDE, ANTIANDROGEN, SURVIVAL, ARN-509, 3126 Surgery, anesthesiology, intensive care, radiology",

author = "Christophe Massard and Penttinen, {Heidi M.} and Egils Vjaters and Petri Bono and Vilnis Lietuvietis and Tammela, {Teuvo L.} and Annamari Vuorela and Pirjo Nykanen and Pasi Pohjanjousi and Amir Snapir and Karim Fizazi",

year = "2016",

month = may,

doi = "10.1016/j.eururo.2015.09.046",

language = "English",

volume = "69",

pages = "834--840",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier Scientific Publ. Co",

number = "5",

}

Massard, C, Penttinen, HM, Vjaters, E, Bono, P, Lietuvietis, V, Tammela, TL, Vuorela, A, Nykanen, P, Pohjanjousi, P, Snapir, A & Fizazi, K 2016, 'Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study', European Urology, vol. 69, no. 5, pp. 834-840. https://doi.org/10.1016/j.eururo.2015.09.046

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer : An Open-label Phase 1 Study. / Massard, Christophe; Penttinen, Heidi M.; Vjaters, Egils et al.

In: European Urology, Vol. 69, No. 5, 05.2016, p. 834-840.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer

T2 - An Open-label Phase 1 Study

AU - Massard, Christophe

AU - Penttinen, Heidi M.

AU - Vjaters, Egils

AU - Bono, Petri

AU - Lietuvietis, Vilnis

AU - Tammela, Teuvo L.

AU - Vuorela, Annamari

AU - Nykanen, Pirjo

AU - Pohjanjousi, Pasi

AU - Snapir, Amir

AU - Fizazi, Karim

PY - 2016/5

Y1 - 2016/5

KW - Androgen receptor inhibitor

KW - Castration-resistant prostate cancer

KW - ODM-201

KW - ENZALUTAMIDE

KW - ANTIANDROGEN

KW - SURVIVAL

KW - ARN-509

KW - 3126 Surgery, anesthesiology, intensive care, radiology

U2 - 10.1016/j.eururo.2015.09.046

DO - 10.1016/j.eururo.2015.09.046

M3 - Article

VL - 69

SP - 834

EP - 840

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -